UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C.

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): June 29, 2020

 

BIOMERICA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

17571 Von Karman Ave.

Irvine, California 92614

(Address of Principal Executive Offices

Including Zip Code)

 

949-645-2111

(Registrant’s Telephone Number,

Including Area Code)

 

Not applicable

 

(Former Name or Former Address if Changed

Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

1

 

o         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

2

 

Item 7.01 Regulation FD Disclosures

 

On June 29, 2020, Biomerica, Inc. (“Biomerica”) issued a press release announcing that it has signed a definitive agreement with the University of Texas Health Science Center at Houston to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.

 

The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01  Other Events

 

On June 25, 2020, Biomerica, Inc. signed a definitive agreement with the University of Texas Health Science Center at Houston to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.

 

Item 9.01        Financial Statements and Exhibits

 

(d)  Exhibits

 

 

Number           Description

 

99.1                 Press Release issued June 29, 2020.

 

3

 

SIGNATURE

 

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  June 30, 2020	Biomerica, Inc.
	By:	/s/ Zackary S. Irani
		Zackary S. Irani
		Chief Executive Officer

 

4